Prognostic analysis of hepatitis B cirrhosis patients with hypovolemia based on hypersensitivity test
Objective To investigate the clinical characteristics and prognosis of hepatitis B cirrhosis patients with lymphatic leukaemia virus(LLV)treated with nucleotide analogs(NAs).Methods NAs-treated patients with hepatitis B cirrhosis admitted to the Third People's Hospital of Taiyuan from 2020 to 2022 were collected and divided into undetected target group,VLLV group,and LLV group through hypersensitivity detection of hepatitis B virus(HBV).The patients were followed up for an average of 48 weeks to observe the clinical characteristics,complications related to cirrhosis,and the incidence of hepatocellular carcinoma(HCC),and evaluate the prognosis and influencing factors.Results Among 251 patients with hepatitis B cirrhosis treated with NAs,25 were in the LLV group(HBV DNA10-2 000 U/ml),107 were VLLV group(HBV DNA＜10 U/ml),and 119 were in the undetected target group(HBV DNA undetected).Alanine aminotransferase,aspartate aminotransferase,serum albumin,total bilirubin,and prothrombin activity(PTA)％were statistically significant among the three groups.The history of NAs therapy and interferon(IFN)therapy in the 3 groups had statistical significance,and most of the patients received 1-2 kinds of NAs antiviral therapy,and more than half of the patients could achieve the effect of HBV DNA undetectable.During follow-up,new cirrhosis-related complications were found in all three groups,and 38 patients(15.1％)developed HCC,including 7 deaths.Conclusion The better the control of HBV DNA,the lighter the liver injury and the better the liver synthesis function.Receiving antiviral therapy(NAs or IFN)can significantly reduce HBV DNA.Patients with hepatitis B cirrhosis,regardless of complete response to antiviral therapy,should be regularly examined,for early detection of cirrhosis-related complications and HCC,and take active treatment to reduce related mortality.
Hepatitis BLiver cirrhosisViremiaLiver neoplasmsDNA tests
万方数据
维普
